GLENMARK PHARMACEUTICALS reported revenue of ₹3,932 cr and net profit of ₹483 cr in Q1 FY27 (quarter ended 30 Jun 2026), +930.3% year on year. Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated automatically from exchange filings.
Next results date
5 Nov 2026
To consider and approve the financial results for the period ended September 30, 2026
GLENMARK PHARMACEUTICALS (GLENMARK) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹3,932 cr and a net profit of ₹483 cr, translating into earnings per share of ₹17.11.
Compared with the same quarter a year earlier, revenue grew strongly by +28.5% and net profit grew sharply by +930.3%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹632 cr, an operating margin of 16.1% versus 14.7% a year ago — a gain of 1.3 percentage points.
GLENMARK quarter-wise results table
Revenue
₹3,932 cr
+28.5%YoY
Net profit
₹483 cr
+930.3%YoY
Operating profit
₹632 cr
+40.2%YoY
EPS
₹17.11
+930.7%YoY
GLENMARK PHARMACEUTICALS (GLENMARK) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth
Quarter
Revenue
Operating profit
Net profit
OPM
Net margin
EPS
Profit YoY
Profit QoQ
Q1 FY272026-06-30
₹3,932 cr
₹632 cr
₹483 cr
16.1%
12.3%
₹17.11
+930.3%
+60.2%
Q4 FY262026-03-31
₹3,760 cr
₹615 cr
₹301 cr
16.3%
8.0%
₹10.68
—
-25.2%
Q3 FY262025-12-31
₹3,888 cr
₹715 cr
₹403 cr
18.4%
10.4%
₹14.29
—
-33.9%
Q2 FY262025-09-30
₹6,004 cr
₹2,218 cr
₹610 cr
36.9%
10.2%
₹21.63
—
+1202.2%
Q1 FY262025-06-30
₹3,059 cr
₹451 cr
₹46.87 cr
14.7%
1.5%
₹1.66
—
—
TTM (last 4 quarters)
₹17,584 cr
₹4,180 cr
₹1,798 cr
23.8%
10.2%
₹63.71
—
—
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
GLENMARK quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
GLENMARK PHARMACEUTICALS quarterly income statement
Particulars
Q1 FY272026-06-30
Q4 FY262026-03-31
Q3 FY262025-12-31
Q2 FY262025-09-30
Q1 FY262025-06-30
Revenue / Sales
₹3,932 cr
₹3,760 cr
₹3,888 cr
₹6,004 cr
₹3,059 cr
Total expenses
₹3,300 cr
₹3,146 cr
₹3,173 cr
₹3,785 cr
₹2,609 cr
Gross profit
₹2,686 cr
₹2,588 cr
₹2,593 cr
₹4,739 cr
₹2,044 cr
Operating profit (EBIT)
₹632 cr
₹615 cr
₹715 cr
₹2,218 cr
₹451 cr
Operating margin
16.1%
16.3%
18.4%
36.9%
14.7%
Interest cost
₹54 cr
₹42.6 cr
₹41.43 cr
₹66.46 cr
₹58.23 cr
Profit before tax
₹643 cr
₹388 cr
₹534 cr
₹967 cr
₹95.58 cr
Tax expense
₹161 cr
₹86.45 cr
₹131 cr
₹357 cr
₹48.61 cr
Effective tax rate
25.0%
22.3%
24.5%
36.9%
50.9%
Net profit (PAT)
₹483 cr
₹301 cr
₹403 cr
₹610 cr
₹46.87 cr
Net profit margin
12.3%
8.0%
10.4%
10.2%
1.5%
Basic EPS
₹17.11
₹10.68
₹14.29
₹21.63
₹1.66
Diluted EPS
₹17.11
₹10.68
₹14.28
₹21.62
₹1.66
GLENMARK results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter
Growth
Q1 FY27
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Revenue YoY
+28.5%
—
—
—
—
Revenue QoQ
+4.6%
-3.3%
-35.2%
+96.2%
—
Operating profit YoY
+40.2%
—
—
—
—
Operating profit QoQ
+2.8%
-14.1%
-67.8%
+392.3%
—
Net profit YoY
+930.3%
—
—
—
—
Net profit QoQ
+60.2%
-25.2%
-33.9%
+1202.2%
—
EPS YoY
+930.7%
—
—
—
—
EPS QoQ
+60.2%
-25.3%
-33.9%
+1203.0%
—
GLENMARK annual results history
Full-year performance for GLENMARK PHARMACEUTICALS, useful for reading each quarter in context.
GLENMARK PHARMACEUTICALS annual income statement
Particulars
FY262026-03-31
FY252025-03-31
FY242024-03-31
FY232023-03-31
Revenue / Sales
₹16,711 cr
₹13,146 cr
₹11,635 cr
₹11,432 cr
Total expenses
₹12,688 cr
₹11,277 cr
₹11,004 cr
₹10,353 cr
Gross profit
₹11,597 cr
₹8,388 cr
₹6,756 cr
₹6,845 cr
Operating profit (EBIT)
₹4,023 cr
₹1,868 cr
₹631 cr
₹1,079 cr
Operating margin
24.1%
14.2%
5.4%
9.4%
Interest cost
₹209 cr
₹207 cr
₹516 cr
₹349 cr
Profit before tax
₹1,985 cr
₹1,399 cr
₹36.5 cr
₹240 cr
Tax expense
₹623 cr
₹352 cr
₹1,867 cr
₹329 cr
Effective tax rate
31.4%
25.2%
5116.7%
137.3%
Net profit (PAT)
₹1,362 cr
₹1,047 cr
-₹1,502 cr
₹297 cr
Net profit margin
8.1%
8.0%
-12.9%
2.6%
Basic EPS
₹48.26
₹37.11
₹-53.22
₹10.53
Diluted EPS
₹48.24
₹37.11
₹-53.22
₹10.53
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹3,932 cr against ₹3,059 cr in Q1 FY26, and ₹3,760 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +4.6%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹3,300 cr, or 83.9% of revenue, with operating profit grew +40.2% year on year.
Margins, tax and profitability
Net profit of ₹483 cr works out to a net margin of 12.3% compared with 1.5% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, GLENMARK PHARMACEUTICALS reported profit before tax of ₹643 cr, a tax charge of ₹161 cr (effective rate 25.0%), interest cost of ₹54 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹301 cr in Q4 FY26 to ₹483 cr in Q1 FY27, a change of +60.2%.
Trailing twelve months and annual context
Across the trailing four quarters GLENMARK PHARMACEUTICALS has generated revenue of ₹17,584 cr and net profit of ₹1,798 cr, a trailing net margin of 10.2%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹16,711 cr with net profit of ₹1,362 cr and EPS of ₹48.26, versus the prior year where revenue grew +27.1% and profit grew +30.1%.
What to watch in the next GLENMARK quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
GLENMARK PHARMACEUTICALS has intimated the exchange that its board meets on 5 Nov 2026 to approve the next set of financial results; this page and the tables above update automatically once that filing lands.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
GLENMARK results coverage
No results report published for GLENMARK yet — our desk covers each quarter within minutes of the filing.
What were GLENMARK PHARMACEUTICALS (GLENMARK) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), GLENMARK PHARMACEUTICALS reported revenue of ₹3,932 cr and net profit of ₹483 cr, a change of +930.3% year on year on +28.5% revenue growth. EPS stood at ₹17.11.
What is GLENMARK profit margin in Q1 FY27?
GLENMARK PHARMACEUTICALS posted a net profit margin of 12.3% and an operating margin of 16.1% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹17,584 cr and net profit ₹1,798 cr.
Did GLENMARK results beat the previous quarter?
GLENMARK PHARMACEUTICALS net profit changed +60.2% quarter on quarter, from ₹301 cr in Q4 FY26 to ₹483 cr in Q1 FY27.
When are GLENMARK PHARMACEUTICALS (GLENMARK) quarterly results?
The board of GLENMARK PHARMACEUTICALS meets on 5 Nov 2026 to consider and approve the financial results, as per the exchange filing.
Where can I see GLENMARK latest quarterly results?
Results coverage for GLENMARK will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the GLENMARK stock page.
What is GLENMARK PHARMACEUTICALS annual revenue and profit?
For FY26, GLENMARK PHARMACEUTICALS reported full-year revenue of ₹16,711 cr and net profit of ₹1,362 cr, with EPS of ₹48.26.
How many quarterly results has GLENMARK declared recently?
Past results dates for GLENMARK will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 26 Oct 2026. For information only, not investment advice.
